+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Brain tyrosine depletion attenuates haloperidol-induced striatal dopamine release in vivo and augments haloperidol-induced catalepsy in the rat



Brain tyrosine depletion attenuates haloperidol-induced striatal dopamine release in vivo and augments haloperidol-induced catalepsy in the rat



Psychopharmacology 172(1): 100-107



There are conflicting reports as to whether alterations in tyrosine levels affect functional indices of striatal dopamine (DA) transmission. Since the DA antagonist haloperidol (HAL) increases striatal DA release and induces catalepsy through its actions on striatal DA systems, it provides a useful paradigm to assess both neurochemical and behavioral effects of lowering brain tyrosine levels. To determine how brain tyrosine depletion affects HAL-induced catalepsy and striatal DA release in awake, freely moving rats. In male rats, a control or tyrosine- and phenylalanine-free neutral amino acid solution NAA(-) (IP) was administered 30-60 min prior to HAL (IP). In one cohort, striatal microdialysate was assayed for DA levels. In a parallel cohort, catalepsy was measured using the bar test. NAA (-) reduced striatal tyrosine levels by 60%. The latter did not affect basal striatal DA release, but consistently delayed the attainment of maximal HAL-induced (0.19 mg/kg and 0.25 mg/kg SC) striatal DA release; the latter was abolished by administration of tyrosine. NAA(-) also potentiated HAL-induced catalepsy. Acute brain tyrosine depletion attenuates HAL-induced striatal DA release and potentiates haloperidol-induced catalepsy. Both effects can be reversed by administration of tyrosine. Overall, the data indicate that tyrosine depletion affects both neurochemical and behavioral indices of striatal DA release.

(PDF emailed within 0-6 h: $19.90)

Accession: 011817294

Download citation: RISBibTeXText

PMID: 14586541

DOI: 10.1007/s00213-003-1619-3


Related references

TYROSINE DEPLETION AUGMENTS HALOPERIDOL - INDUCED CATALEPSY AND ATTENUATES HALOPERIDOL - INDUCED DOPAMINE RELEASE IN THE STRIATUM OF THE RAT As MEASURED BY in vivo MICRODIALYSIS. Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 536 3, 2002

The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo: Opposite role of 5-HT2A and 5-HT2C receptor subtypes and significance of the haloperidol dose used. Neuropharmacology 39(6): 1053-1063, April 3, 2000

Tyrosine augments acute clozapine- but not haloperidol-induced dopamine release in the medial prefrontal cortex of the rat: an in vivo microdialysis study. Neuropsychopharmacology 25(1): 149-156, 2001

8-OH-DPAT, a 5-HT-1A agonist and ritanserin, a 5-HT-2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology. 131(1): 57-63, 1997

Mirtazapine enhances the effect of haloperidol on apomorphine-induced climbing behaviour in mice and attenuates haloperidol-induced catalepsy in rats. Psychopharmacology. 135(3): 284-289,. 1, 1998

Halothane Attenuates the Haloperidol Induced Dopamine Release and Enhanced the Clozapine Induced Dopamine Release in the Striatum of Rat Using In Vivo Microdialysis Study. Anesthesiology Abstracts of Scientific Papers Annual Meeting (2001): Abstract No A-719, 2002

The alpha2-adrenoceptor antagonist idazoxan reverses catalepsy induced by haloperidol in rats independent of striatal dopamine release: Role of serotonergic mechanisms. Neuropsychopharmacology 28(5): 872-879, 2003

LOCAL TYROSINE ADMINISTRATION AFFECTS CLOZAPINE - INDUCED DOPAMINE RELEASE IN MEDIAL PREFRONTAL CORTEX AND HALOPERIDOL - INDUCED DOPAMINE RELEASE IN STRIATUM AN in vivo MICRODIALYSIS STUDY IN THE RAT. Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 536 4, 2002

Conditional tolerance to haloperidol-induced catalepsy is not caused by striatal dopamine receptor supersensitivity. Psychopharmacology 90(1): 54-57, 1986

Conditional tolerance to haloperidol-induced catalepsy: striatal dopamine receptor supersensitivity is a possible explanation. Psychopharmacology 95(1): 142-145, 1988

MK 801 reverses haloperidol-induced catalepsy from both striatal and extrastriatal sites in the rat brain. European Journal Of Pharmacology. 332(2): 153-160, 1997

Haloperidol-induced plasma prolactin release: sensitivity, reliability, and comparison to haloperidol antagonism of dopamine agonist-induced stereotyped behavior in the rat. Psychopharmacology 78(4): 383-384, 1982

Ceruletide, a cholecystokinin-related peptide, attenuates haloperidol-induced increase in dopamine release from the rat striatum: an in vivo microdialysis study. Brain Research 519(1-2): 44-49, 1990

Effects of aminooxy acetic acid and baclofen on the catalepsy and on the increase of meso limbic and striatal dopamine turnover induced by haloperidol in rats. Acta Pharmacologica et Toxicologica 39(3): 393-400, 1976

Effect of acute morphine or haloperidol administration on catalepsy and striatal dopamine turnover in rats chronically treated with morphine or haloperidol. Pharmacologist: 259, 1973